Hani Babiker, MD
Hematology & Oncology · Jacksonville, FLNPI 1801055595
Payments from drug & device makers
Across 826 payments — averaging $3334.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$563K
- E.r. Squibb & Sons, L.L.C.$408K
- Pfizer$356K
- Regeneron$245K
- Bayer$213K
- Novocure GmbH$200K
- plus $770K from 22 others
Across 5 payments — averaging $1007.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4K
- Bristol Myers Squibb$476
- Regeneron$92
What the payments were for
- Consulting fees$20,04038%
- Speaking & faculty fees$22,03842%
- Travel & lodging$6,72113%
- Food & beverage$3,5227%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 98 | $562,539 |
| E.r. Squibb & Sons, L.L.C. | 6 | $408,115 |
| Pfizer | 50 | $356,308 |
| Regeneron | 40 | $244,577 |
| Bayer | 102 | $212,819 |
| Novocure GmbH | 2 | $200,000 |
| Eli Lilly | 9 | $133,557 |
| AstraZeneca | 5 | $89,873 |
| Kyowa Kirin Co., Ltd | 13 | $84,445 |
| Incyte Corporation | 83 | $81,998 |
| Daiichi Sankyo Inc. | 340 | $73,382 |
| AbbVie | 5 | $63,600 |
| Mirati Therapeutics, Inc. | 1 | $62,422 |
| Blue Earth Diagnostics | 5 | $52,407 |
| Bristol Myers Squibb | 1 | $37,086 |
| Ipsen Biopharmaceuticals, Inc | 31 | $29,921 |
| Genentech, Inc. | 1 | $28,500 |
| Merck | 23 | $17,976 |
| Servier Bioinnovation | 1 | $6,000 |
| Modernatx, Inc. | 2 | $5,498 |
| Exelixis Inc. | 1 | $1,650 |
| Coherus Oncology, Inc. | 1 | $900 |
| Astrazeneca UK Limited | 1 | $450 |
| Taiho Oncology, Inc. | 1 | $104 |
| Genentech USA, Inc. | 1 | $90 |
| Astellas Pharma Global Development | 1 | $21 |
| Gilead | 1 | $20 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,754,269 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 18 | $138 |
| Prochlorperazine Maleate | 11 | $106 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Jacksonville
- Steven AttiaJacksonville$13.9M
- Sikander AilawadhiJacksonville$9.8M
- Vamsidhar VelchetiJacksonville$8.2M
- Asher Chanan KhanJacksonville$5.8M
- Yanyan LouJacksonville$4.8M
- Arnab BasuJacksonville$4.6M
- James ForanJacksonville$4.6M
- Jennifer CrozierJacksonville$3.5M
- Ayed AyedJacksonville$3.4M
- Saranya ChumsriJacksonville$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.